Baymix Latibon Plus Me Formulation:   Each kilogram contains:   Calcium Formate...... 360 g Calcium Lactate.......150 g Calcium Citrate........150 g Phosphoric Acid.......135 g Citric Acid..............60 g   Formic Acid.........50 g Lactic Acid..........43 g Sorbic Acid.........30 g Malic Acid..........45 g Feed Premix Powder Philippines - English - FDA (Food And Drug Administration)

baymix latibon plus me formulation: each kilogram contains: calcium formate...... 360 g calcium lactate.......150 g calcium citrate........150 g phosphoric acid.......135 g citric acid..............60 g formic acid.........50 g lactic acid..........43 g sorbic acid.........30 g malic acid..........45 g feed premix powder

elanco philippines, inc.; distributor: elanco philippines, inc. - calcium , phosphorus , organic acids (vet.) - feed premix powder - formulation: each kilogram contains: calcium formate...... 360 g calcium lactate.......150 g calcium citrate........150 g phosphoric acid.......135 g citric acid..............60 g formic acid.........50 g lactic acid..........43 g sorbic acid.........30 g malic acid..........45 g

SABAKEM TRALKOXYDIM 400WG HERBICIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem tralkoxydim 400wg herbicide

sabakem pty ltd - tralkoxydim - water dispersible granule - tralkoxydim cyclohexanediones active 400.0 g/kg - herbicide - barley | barley - see label for exceptions | cereal rye | triticale | wheat - annual or wimmera ryegrass | annual phalaris | lesser canary grass - suppression | paradoxa grass - suppression | wild oat | canary grass | rigid ryegrass | wimmera ryegrass

PENNCOZEB FUNGICIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

penncozeb fungicide

upl australia pty ltd - mancozeb - wettable powder - mancozeb carbamate-dithiocarbamate active 800.0 g/kg - fungicide - almond | apple | apricot | banana | bean | beetroot | broad bean | broccoli | brussels sprouts | cabbage | capsicum or pepper | - alternaria leaf blight or spot blight | alternaria spot | angular leaf spot - p. griseola | anthracnose | anthracnose on bean | anthracnose on cucurbit | anthracnose on mango | bitter rot | black pit | black spot - colletotrichum acutatum | black spot on citrus | black spot on rose | black spot/scab in apple/pear | blight | blue mould on tobacco | botrytis leaf spot or corm collar rot | brown citrus rust mite | brown rot | brown spot on passionfruit | brown spot on tobacco | cercospora leaf spot | cercospora leaf spot - banana | chocolate spot on bean | citrus bud mite | citrus rust mite or maori mite | cordana leaf spot | downy mildew | downy mildew on cucurbit | downy mildew on lettuce | early blight (target spot) | fly speck | freckle or scab on stone fruit | frog eye spot on tobacco | fruit freckle | fusarium seedpiece rot | fusarium spp. | grey leaf spot - pyricularia grisea | grey mould - botrytis cinerea | gummy stem blight on cucurbit | helminthosporium disease | late blight or irish blight | leaf bli

STERILE WATER injection United States - English - NLM (National Library of Medicine)

sterile water injection

vettek - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - water 500 ml in 500 ml - for animal use only

Nilstat Oral Capsules Australia - English - Department of Health (Therapeutic Goods Administration)

nilstat oral capsules

aspen pharma pty ltd - nystatin, quantity: 500000 iu - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; ethanol; iron oxide yellow; titanium dioxide; gelatin; isopropyl alcohol; shellac; carbon black - indications as at 24 may 2005 : nilstat oral is indicated for the treatment of intestinal candidiasis.

RAMIPRIL WINTHROP ramipril 10mg capsule hard blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ramipril winthrop ramipril 10mg capsule hard blister pack

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; indigo carmine; iron oxide black; titanium dioxide; pregelatinised maize starch - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

RAMIPRIL SANDOZ ramipril 10mg capsule hard blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

ramipril sandoz ramipril 10mg capsule hard blister pack

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; indigo carmine; iron oxide black; pregelatinised maize starch; erythrosine; titanium dioxide - treatment of hypertension. (data are currently not available to support the use of ramipril sandoz in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.